After hours:
Chart Events
Performance Outlook
| Previous Close | 2.2600 |
| Open | 2.1300 |
| Bid | 1.9500 x 900 |
| Ask | 2.3000 x 1300 |
| Day's Range | 2.0900 - 2.3500 |
| 52 Week Range | 1.3900 - 4.2650 |
| Volume | |
| Avg. Volume | 351,696 |
| Market Cap | 12.704M |
| Beta (5Y Monthly) | 1.66 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.1200 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Immuron US DoD Naval Medical Research Center responds to FDA Clinical Hold for New Campylobacter ETEC Therapeutic
MELBOURNE, Australia, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, today announces that a response letter has been submitted to the US Food and Drug Administration (FDA). Immuron has previously reported feedback was received from the FDA following a review of the Investigation
- GlobeNewswire
US Department of Defense Uniformed Services University Clinical Evaluation of Travelan™ Achieves 150 Recruitment Milestone
Highlights: First participants enrolled in USU Travelan Clinical Trial Field Study157 participants successfully randomized into the Clinical StudyPlans in place to enrol in 1302 healthy volunteers in total Infectious diarrhea is the most common illness reported by travelers & military personnel MELBOURNE, Australia, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially
- GlobeNewswire
Immuron Receives European Patent on Drug Composition to Treat Clostridioides difficile Associated Disease
MELBOURNE, Australia, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to announce that has been granted a European Patent for compositions and methods for the treatment and/or prophylaxis of Clostridioides difficile associated disease. Notification of the decision to g
